Navigation Links
FDA Proposes Tighter Regulation of Public Defibrillators

By Steven Reinberg
HealthDay Reporter

FRIDAY, March 22 (HealthDay News) -- To improve the quality of lifesaving devices called automated external defibrillators, the U.S. Food and Drug Administration proposed Friday that the seven manufacturers of these devices be required to get agency approval for their products.

Automated external defibrillators (AEDs) are portable devices that deliver an electrical shock to the heart to try to restore normal heart rhythms during cardiac arrest. Although the FDA is not recalling AEDs, the agency said that it is concerned with the number of recalls and quality problems associated with them.

"[The] FDA is not questioning the clinical utility of AEDs," Dr. William Maisel, chief scientist in FDA's Center for Devices and Radiological Health, said during a press conference on Friday announcing the proposal.

"These devices are critically important and serve a very important public health need. The importance of early defibrillation for patients who are suffering from cardiac arrest is well-established," he said.

Maisel added the FDA is not calling into question the safety or quality of AEDs currently in place around the country.

There are about 2.4 million such devices in public places throughout the United States, according to The New York Times.

"Today's action does not require the removal or replacement of AEDs that are in distribution. Patients and the public should have confidence in these devices, and we encourage people to use them under the appropriate circumstances," Maisel said.

Although there have been problems with AEDs, their lifesaving benefits outweigh the risk of making them unavailable, Maisel explained.

Dr. Moshe Gunsburg, director of cardiac arrhythmia service and co-chief of the division of cardiology at Brookdale University Hospital and Medical Center in Brooklyn, N.Y., supports the FDA proposal.

"Cardiac arrest is the leading cause of death in the United States. It claims over 250,000 lives a year," he said.

Early defibrillation is the key to helping patients survive, Gunsburg said. Timing, however, is critical. If a patient is not defibrillated within four to six minutes, brain damage starts and the odds of survival diminish with each passing minute, which is why 90 percent of these patients don't survive, he explained.

The best chance a patient has is an automated external defibrillator used quickly, which is why Gunsburg and others want AEDs to be as common as fire extinguishers so laypeople can use them when they see someone go into cardiac arrest. The FDA's action will help ensure that these devices are in top shape when they are needed, he said.

But, there have been problems and failures with AEDs. Between 2005 and 2012 the FDA received about 45,000 reports of failure of these devices. In addition, there have been 88 recalls, Maisel said.

According to Maisel, it isn't known whether failures of AEDs cause any deaths. That's because when these devices are used, patients are in cardiac arrest and most die even when an AED is used and works well, he said.

However, machine defects may have contributed to patient deaths, the Times reported. For example, in one case, a nurse was attempting to attach a patient in cardiac arrest to a defibrillator when the device's screen read "memory full." In another case, a problem with a defibrillator's software caused the device to read "equipment disabled" as it was being used on a patient. In both cases, the patient died, the newspaper said.

The actual number of AED failures is also not known, but, "it's quite small," Maisel said. The most common problems are random power shutdowns, erroneous error messages and failure of the components of the machine, he noted.

"Tens of thousands of adverse events is too many. We think 88 recalls are too many," Maisel said.

"So, by calling for pre-market approval we can focus our attention on the types of problems that have been observed and our expectation is that we will observe an improvement in the reliability over time with these devices," he said.

This action is being taken based on the recommendation of the FDA's Circulatory System Devices Panel, which wants AEDs to be a Class III medical device requiring pre-market approval.

AEDs were on the market before the current approval process for Class III medical devices was updated, so they didn't need pre-market approval. But given their problems they should now require approval, Maisel said.

In addition to the safety and effectiveness data, the application must include a review of a manufacturer's quality systems and an inspection of its plant.

According to the FDA, after the device is approved, the manufacturer must submit any significant changes made to the device, as well as a yearly report on the device's performance.

The public will have 90 days to comment on the FDA proposal. When the proposal becomes final, the process of getting all AEDs approved will take about two years, Maisel said.

More information

For more information on automated external defibrillators, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Moshe Gunsburg, M.D., director, cardiac arrhythmia service, co-chief, division of cardiology, Brookdale University Hospital and Medical Center, Brooklyn, N.Y.; March 22, 2013, press conference with William Maisel, M.D., M.P.H., deputy director of science and chief scientist, Center for Devices and Radiological Health, U.S. Food and Drug Administration; The New York Times

Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Proposes New Rules to Strengthen Food Safety
2. EPA Proposes New Cuts on Levels of Soot in Air
3. IADR/AADR publish studies on severe early childhood caries - proposes new classification
4. Nouvelle Research, Inc. studies show chronic inflammation reduction through NRF2 Upregulation and NF-kB Downregulation, Cur-OST® Supplements Positively Impact Health
5. GW researcher receives federal grant to study hedgehog regulation of cell-cell interaction
6. American Emu Association Updates Quality Regulations in Response to Fraudulent Oils in Market
7. Abnormal growth regulation may occur in children with heart defects
8. Growing medicines in plants requires new regulations
9. FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
10. I Fly First Class Announces Very Important New Tips and Regulation For Travelers
11. Dec. 12 Atlantic Information Services Webinar to Address the Nuances of New HHS Essential Health Benefits Regulations
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology: